{{Drugbox
| Watchedfields = changed
| verifiedrevid = 443725104
| IUPAC_name = 4-Methyl-5-{[4-(methylsulfanyl)phenyl]carbonyl}-2,3-dihydro-1''H''-imidazol-2-one
| image = Enoximone.svg

<!--Clinical data-->
| tradename = Perfan
| Drugs.com = {{drugs.com|international|enoximone}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_UK = POM
| legal_US = <!-- OTC / Rx-only  -->
| legal_status =  
| routes_of_administration = [[Intravenous therapy|Intravenous]]

<!--Pharmacokinetic data-->
| bioavailability = 50% (oral)
| protein_bound = 85%
| metabolism = [[Liver]] ([[oxidation]])
| elimination_half-life = 4 to 10 hours
| excretion = [[Kidney|Renal]] (60 to 70%)

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 77671-31-9
| ATC_prefix = C01
| ATC_suffix = CE03
| PubChem = 53708
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB04880
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 48492
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = C7Z4ITI7L7
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04004
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 249856

<!--Chemical data-->
| C=12 | H=12 | N=2 | O=2 | S=1
| molecular_weight = 248.302 g/mol
| smiles = O=C(/C1=C(/NC(=O)N1)C)c2ccc(SC)cc2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZJKNESGOIKRXQY-UHFFFAOYSA-N
| melting_point = 255
| melting_high = 258
| melting_notes = (decomposes)
}}

'''Enoximone''' ([[International Nonproprietary Name|INN]], trade name '''Perfan''') is an [[imidazole]] [[phosphodiesterase inhibitor]]. It is used in the treatment of [[congestive heart failure]] and is selective for [[PDE3 inhibitor|phosphodiesterase 3]].<ref name="pmid17714066">{{cite journal |vauthors=Boldt J, Suttner S |title=Combined use of ultra-short acting beta-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone |journal=Expert Opin Pharmacother |volume=8 |issue=13 |pages=2135–47 |date=September 2007 |pmid=17714066 |doi=10.1517/14656566.8.13.2135 |url=}}</ref>

==Synthesis==
<ref name="SchnettlerDage1982">{{cite journal|last1=Schnettler|first1=Richard A.|last2=Dage|first2=Richard C.|last3=Grisar|first3=J. Martin|title=4-Aroyl-1,3-dihydro-2H-imidazol-2-ones, a new class of cardiotonic agents|journal=Journal of Medicinal Chemistry|volume=25|issue=12|year=1982|pages=1477–1481|issn=0022-2623|doi=10.1021/jm00354a017}}</ref>

Prepn: {{Cite patent|BE|883856}} (1980 to Richardson-Merrell); R. A. Schnettler et al., {{US patent|4405635}} (1983 to Merrell-Dow)

==References==
{{reflist}}

{{Phosphodiesterase inhibitors}}
{{Cardiac stimulants excluding cardiac glycosides}}

[[Category:Cardiac stimulants]]
[[Category:Imidazolines]]
[[Category:Inotropic agents]]
[[Category:Ketones]]
[[Category:Lactams]]
[[Category:PDE3 inhibitors]]
[[Category:Thioethers]]
[[Category:Ureas]]

{{cardiovascular-drug-stub}}